Autolus Therapeutics Reports $20.9M Product Revenue in Q2 2025, Net Loss of $47.9M

Autolus Therapeutics plc reported its financial results for the second quarter of 2025, highlighting a significant increase in product revenue following the launch of its CAR T therapy, AUCATZYL. The company generated $20.9 million in product revenue for the three months ended June 30, 2025, compared to no revenue in the same period last year, marking a 100% increase. For the first half of 2025, total revenue reached $29.9 million, a substantial rise from $10.1 million in the prior year, primarily due to the commercialization of AUCATZYL, which received FDA approval in November 2024.

Despite the revenue growth, Autolus reported a net loss of $47.9 million for the second quarter, a decrease from a loss of $58.3 million in the same quarter of 2024. The company’s accumulated deficit increased to $1.22 billion as of June 30, 2025, up from $1.10 billion at the end of 2024. The cost of sales for the quarter was $24.4 million, reflecting the expenses associated with the production and delivery of AUCATZYL. Research and development expenses decreased by 25% to $27.4 million, attributed to a reallocation of resources towards commercial manufacturing following the product's approval.

Operationally, Autolus has made strides in expanding its market presence, with 46 cancer treatment centers activated in the U.S. as of August 2025, and coverage secured for over 90% of U.S. medical lives. The company is also navigating regulatory landscapes in the U.K. and EU, having received conditional marketing authorization for AUCATZYL in the U.K. and full approval in the EU for patients aged 26 and older. However, the company faces challenges in securing funding from the National Institute for Health and Care Excellence (NICE) in the U.K., which has recommended against funding for AUCATZYL.

Looking ahead, Autolus anticipates continued operating losses as it invests in the commercialization of AUCATZYL and advances its pipeline of product candidates. The company reported cash and cash equivalents of $123.8 million and marketable securities of $330.5 million as of June 30, 2025, which it believes will be sufficient to fund operations for at least the next twelve months. However, the company acknowledges the need for additional capital to support its ongoing development and commercialization efforts, emphasizing the uncertainty surrounding future funding and operational strategies.